Evidence map›Paper›PMID 41131963›Full record

ArticleScandinavian journal of immunology2025

The Nuclear Receptor Nurr1 Modulates the Expression and Activity of PPARγ in Human Pro-Inflammatory Macrophages.

Eduardo Santana-Cisneros, Miguel A Solís-Barbosa, Norma C Segovia-Gamboa, Marco A Meraz-Ríos, Erika González-Domínguez, Rosaura Hernández-Rivas, Daniel Marrero-Rodríguez, Carmen Sanchez-Torres

Abstract read
In one paragraph

Article in Scandinavian journal of immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Eduardo Santana-CisnerosDepartment of Molecular Biomedicine, Center for Research and Advanced Studies of the National Polytechnic Institute (CINVESTAV-IPN), Mexico City, Mexico.
Miguel A Solís-BarbosaDepartment of Molecular Biomedicine, Center for Research and Advanced Studies of the National Polytechnic Institute (CINVESTAV-IPN), Mexico City, Mexico.
Norma C Segovia-GamboaDepartment of Molecular Biomedicine, Center for Research and Advanced Studies of the National Polytechnic Institute (CINVESTAV-IPN), Mexico City, Mexico.
Marco A Meraz-RíosDepartment of Molecular Biomedicine, Center for Research and Advanced Studies of the National Polytechnic Institute (CINVESTAV-IPN), Mexico City, Mexico.
Erika González-DomínguezEscuela Superior Huejutla, Universidad Autónoma del Estado de Hidalgo, Hujeutla de Reyes, Hidalgo, Mexico.
Rosaura Hernández-RivasDepartment of Molecular Biomedicine, Center for Research and Advanced Studies of the National Polytechnic Institute (CINVESTAV-IPN), Mexico City, Mexico.
Daniel Marrero-RodríguezEndocrine Research Unit, Hospital de Especialidades, Centro Médico Nacional "Siglo XXI", Instituto Mexicano del Seguro Social, Mexico City, Mexico.
Carmen Sanchez-TorresDepartment of Molecular Biomedicine, Center for Research and Advanced Studies of the National Polytechnic Institute (CINVESTAV-IPN), Mexico City, Mexico.ORCID https://orcid.org/0000-0003-0045-8233

Funding

Ministry of Public Education - National Council of Humanities, Science, and Technology A1-S-9430
6 · The paper itself

Abstract

Nurr1 is a member of the nuclear receptor family NR4A that modulates inflammation typically by inhibiting the NF-κB signalling pathway. In vitro, Nurr1 can interact with the peroxisome proliferator-activated receptor (PPAR)γ, as well as be recruited to the Pparg promoter in microglial cells; however, their functional relationship is not established. Here, we aimed to investigate the role of Nurr1 on PPARγ activity in human macrophages. Blood monocytes were cultured with GM-CSF or M-CSF to generate pro- (GM-MDMs) and anti-inflammatory (M-MDMs) macrophages, respectively. The protein levels of PPARγ and Nurr1 were elevated in GM-MDMs compared to M-MDMs, and their expression was positively correlated. PPARγ activation in GM-MDMs with the agonist rosiglitazone did not modify Nurr1 expression. However, Nurr1 activation with the agonist C-DIM12 increased PPARγ levels through protein stabilisation. Further, agonistic activation of Nurr1 decreased the proportion of PPARγ molecules phosphorylated at Ser84, which is a repressive mark for PPARγ transcriptional activity. Accordingly, exposure of GM-MDMs to C-DIM12 enhanced the expression of two PPARγ target genes induced by rosiglitazone, CD36 and PLIN2. Both PPARγ and Nurr1 agonists exhibited anti-inflammatory effects on LPS-stimulated GM-MDMs when administered alone, but C-DIM12 did not globally increase the effectiveness of rosiglitazone under that condition. These findings suggest that Nurr1 enhances PPARγ transcriptional activity, potentially through stabilising PPARγ protein levels and decreasing its repressive phosphorylation at Ser84. This novel mechanism highlights the role of Nurr1 in targeting not only inflammation but additional pathways regulated by PPARγ in macrophages.

Indexed as

InflammationMacrophagesNuclear Receptor Subfamily 4, Group A, Member 2PPAR gammaCells, CulturedGene Expression RegulationGranulocyte-Macrophage Colony-Stimulating FactorHumansPhosphorylationRosiglitazoneSignal TransductionGranulocyte-Macrophage Colony-Stimulating FactorNR4A2 protein, humanNuclear Receptor Subfamily 4, Group A, Member 2PPAR gammaPPARG protein, humanRosiglitazonemacrophagesNurr1PPARγ

Identifiers

PMID41131963
PMCPMC12550473

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.